Lilly’s Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study,…
In an oral presentation from the Digestive Disease Week medical conference in San Diego, California today, Eli Lilly and Company announced new safety and efficacy data for mirikizumab…
Read More...
Read More...
